Effect of glycemic control on intact parathyroid hormone level in end stage renal disease patients on maintenance hemodialysis

Diabetes Research and Clinical Practice

Volumn 105, Issue 3, 2014, Pages 352-355

  Dan, Subhasish ^a   Aditya, Papia ^b   Samanta, Maitreya ^c   Jothimalar, R ^c   Soundarajan, P ^c  

^a MEDICAL COLLEGE AND HOSPITAL   (India)

^b Department of Life Sciences Tejganj High School   (India)

^c SRI RAMACHANDRA UNIVERSITY   (India)

Author keywords

Intact parathyroid hormone; Maintenance hemodialysis; Type 2 diabetes mellitus

Indexed keywords

BICARBONATE; CALCIUM; CALCIUM CARBONATE; GLUCOSE; HEMODIALYSIS FLUID; HEMOGLOBIN A1C; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; POLYSULFONE; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE ASSOCIATION; END STAGE RENAL DISEASE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMODIALYSIS; HUMAN; MAINTENANCE THERAPY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PARATHYROID HORMONE BLOOD LEVEL; TREATMENT DURATION; BLOOD; BONE REMODELING; COMPLICATION; DIAGNOSTIC USE; INDIA; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PHYSIOLOGY; RENAL REPLACEMENT THERAPY;

ADULT; AGED; BLOOD GLUCOSE; BONE REMODELING; CALCIUM; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INDIA; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PARATHYROID HORMONE; RENAL DIALYSIS;

EID: 84921672382     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2014.04.002     Document Type: Article

References (18)

1. Dash S.C., Agarwal S.K. Incidence of chronic kidney disease in India. Nephrol Dial Transplant 2006, 21:232.
2. Mani M.K. Chronic renal failure in India. Nephrol Dial Transplant 1993, 8:684-689.
3. Agarwal S.K., Dash S.C., Irshad M., Raju S., Singh R., Pandey R.M. Prevalence of chronic renal failure in adults in Delhi, India. Nephrol Dial Transplant 2005, 20:1638-1642.
4. Kapur A. Economic analysis of diabetes care. Indian J Med Res 2007, 125(March):473-482.
5. Guariguata L., Whiting D.R., Hambleton I., Beagle J., Linnenkamp U., Shaw J.E. Global estimates of diabetes prevalence for 2013 and projections for 2035 for the IDF diabetes atlas. Diabetes Res Clin Pract 2013, 10.1016/j.diabres.2013.11.002.
6. Hoyland J.A., Picton M.L. Cellular mechanism of renal osteodystrophy. Kidney Int 1999, 56(Suppl. 73):S8-S13.
7. Couttenye M.M., D'Haese P.C., Verschoren W.J., Behets G.J., Schrooten I., DeBroe M.E. Kidney Int 1999, 56(Suppl. 73):S70-S76.
8. Murakami R., Murakami S., Tsushima R., Ueda C., Mikami K., Ebina T., et al. Glycaemic control and serum intact parathyroid hormone levels in diabetic patients on haemodialysis therapy. Nephrol Dial Transplant 2008, 23:315-320.
9. Ali A.R., Emam A.A., Assal H.S., Abbas A.B. Intact parathyroid hormone in Egyptian type 2 diabetics with chronic hemodialysis: impact of glycaemic control. Kidney 2010, 19(1):17-22.
10. National Kidney Foundation, Kidney Disease Outcome Quality Initiative [guide 1, Table 15] [cited in 2003], Available at:. http://www.kidney.org/professionals/KDOQI/guidelines_bone/Guide1.htm.
11. Makita Z., Radoff S., Rayfield E.J., et al. Advanced glycation end products in patients with diabetic nephropathy. N Engl J Med 1991, 325:836-842.
12. Panuccio V., Mallamaci F., Tripepi G., et al. Low parathyroid hormone and pentosidine in hemodialysis patients. Am J Kidney Dis 2002, 40(October (4)):810-815.
13. Yamamoto T., Ozono K., Miyauchi A., et al. Role of advanced glycation end products in adynamic bone disease in patients with diabetic nephropathy. Am J Kidney Dis 2001, 38(4):S161-S164.
14. Paula F.J.M., Lanna C.M.M., Shuhama T., Foss M.C. Effect of metabolic control on parathyroid hormone secretion in diabetic patients. Braz J Med Biol Res 2001, 34:1139-1145.
15. Sugimoto T., Ritter C., Morrissey J., et al. Effects of high concentration of glucose on PTH secretion in parathyroid cells. Kidney Int 1990, 37:1522-1527.
16. Clowes J.A., Robinson R.T., Heller S.R., Eastell R., Blumsohn A. Acute changes of bone turnover and PTH induced by insulin and glucose: euglycemic and hypoglycemic hyperinsulinemic clamp studies. J Clin Endocrinol Metab 2002, 87(7):3324-3329.
17. Weykamp C.W., Penders T.J., Siebelder C.W.M., Muskiet F.A.J., van der Slik W. Interference of carbamylated and acetylated hemoglobins in assays of glycohemoglobin by HPLC, electrophoresis, affinity chromatography and enzyme immunoassay. Clin Chem 1993, 39:138-142.
18. Weykamp C.W., Miedema K., de Haan T., Doelman C.J.A. Carbamylated hemoglobin interference in glycohemoglobin assays. Clin Chem 1999, 45(3):438-440.